nodes	percent_of_prediction	percent_of_DWPC	metapath
Cyclophosphamide—CYP2A6—Methoxsalen—psoriasis	0.057	0.0826	CbGbCtD
Cyclophosphamide—CYP2C8—Tazarotene—psoriasis	0.0436	0.0632	CbGbCtD
Cyclophosphamide—CYP3A5—Beclomethasone—psoriasis	0.0421	0.0611	CbGbCtD
Cyclophosphamide—CYP2A6—Prednisolone—psoriasis	0.0277	0.0402	CbGbCtD
Cyclophosphamide—CYP2B6—Cholecalciferol—psoriasis	0.0246	0.0356	CbGbCtD
Cyclophosphamide—CYP2D6—Hydroxyurea—psoriasis	0.0196	0.0284	CbGbCtD
Cyclophosphamide—CYP2C8—Cholecalciferol—psoriasis	0.0186	0.027	CbGbCtD
Cyclophosphamide—CYP3A7—Hydrocortisone—psoriasis	0.0179	0.026	CbGbCtD
Cyclophosphamide—CYP3A7-CYP3A51P—Hydrocortisone—psoriasis	0.0179	0.026	CbGbCtD
Cyclophosphamide—CYP3A7—Cyclosporine—psoriasis	0.0169	0.0246	CbGbCtD
Cyclophosphamide—CYP3A7-CYP3A51P—Cyclosporine—psoriasis	0.0169	0.0246	CbGbCtD
Cyclophosphamide—CYP3A5—Mycophenolate mofetil—psoriasis	0.0168	0.0243	CbGbCtD
Cyclophosphamide—CYP2A6—Dexamethasone—psoriasis	0.0163	0.0237	CbGbCtD
Cyclophosphamide—CYP2C8—Mycophenolate mofetil—psoriasis	0.0161	0.0234	CbGbCtD
Cyclophosphamide—CYP2C19—Cholecalciferol—psoriasis	0.0156	0.0226	CbGbCtD
Cyclophosphamide—CYP3A4—Calcitriol—psoriasis	0.0146	0.0212	CbGbCtD
Cyclophosphamide—CYP3A5—Hydrocortisone—psoriasis	0.0135	0.0195	CbGbCtD
Cyclophosphamide—CYP2C9—Cholecalciferol—psoriasis	0.013	0.0188	CbGbCtD
Cyclophosphamide—CYP2C8—Hydrocortisone—psoriasis	0.0129	0.0188	CbGbCtD
Cyclophosphamide—CYP3A5—Cyclosporine—psoriasis	0.0127	0.0184	CbGbCtD
Cyclophosphamide—CYP2C8—Cyclosporine—psoriasis	0.0122	0.0177	CbGbCtD
Cyclophosphamide—CYP2D6—Cholecalciferol—psoriasis	0.0119	0.0172	CbGbCtD
Cyclophosphamide—CYP3A4—Methoxsalen—psoriasis	0.0114	0.0165	CbGbCtD
Cyclophosphamide—CYP3A7—Dexamethasone—psoriasis	0.0112	0.0162	CbGbCtD
Cyclophosphamide—CYP3A7-CYP3A51P—Dexamethasone—psoriasis	0.0112	0.0162	CbGbCtD
Cyclophosphamide—ABCB1—Mycophenolate mofetil—psoriasis	0.0109	0.0158	CbGbCtD
Cyclophosphamide—CYP2C19—Prednisone—psoriasis	0.0108	0.0157	CbGbCtD
Cyclophosphamide—CYP2B6—Dexamethasone—psoriasis	0.0106	0.0154	CbGbCtD
Cyclophosphamide—CYP2C19—Cyclosporine—psoriasis	0.0103	0.0149	CbGbCtD
Cyclophosphamide—ABCB1—Betamethasone—psoriasis	0.00937	0.0136	CbGbCtD
Cyclophosphamide—ABCB1—Prednisolone—psoriasis	0.00924	0.0134	CbGbCtD
Cyclophosphamide—ABCB1—Hydrocortisone—psoriasis	0.00876	0.0127	CbGbCtD
Cyclophosphamide—ABCB1—Prednisone—psoriasis	0.00873	0.0127	CbGbCtD
Cyclophosphamide—CYP2C9—Cyclosporine—psoriasis	0.00853	0.0124	CbGbCtD
Cyclophosphamide—CYP3A5—Dexamethasone—psoriasis	0.00837	0.0121	CbGbCtD
Cyclophosphamide—ABCB1—Cyclosporine—psoriasis	0.00827	0.012	CbGbCtD
Cyclophosphamide—CYP2C8—Dexamethasone—psoriasis	0.00805	0.0117	CbGbCtD
Cyclophosphamide—CYP2D6—Cyclosporine—psoriasis	0.0078	0.0113	CbGbCtD
Cyclophosphamide—CYP3A4—Cholecalciferol—psoriasis	0.00754	0.0109	CbGbCtD
Cyclophosphamide—CYP2C19—Dexamethasone—psoriasis	0.00675	0.00979	CbGbCtD
Cyclophosphamide—CYP3A4—Mycophenolate mofetil—psoriasis	0.00654	0.00949	CbGbCtD
Cyclophosphamide—CYP3A4—Triamcinolone—psoriasis	0.00654	0.00949	CbGbCtD
Cyclophosphamide—CYP2C9—Dexamethasone—psoriasis	0.00561	0.00814	CbGbCtD
Cyclophosphamide—CYP3A4—Betamethasone—psoriasis	0.00561	0.00814	CbGbCtD
Cyclophosphamide—CYP3A4—Prednisolone—psoriasis	0.00554	0.00803	CbGbCtD
Cyclophosphamide—ABCB1—Dexamethasone—psoriasis	0.00545	0.0079	CbGbCtD
Cyclophosphamide—CYP3A4—Hydrocortisone—psoriasis	0.00525	0.00761	CbGbCtD
Cyclophosphamide—CYP3A4—Prednisone—psoriasis	0.00523	0.00758	CbGbCtD
Cyclophosphamide—CYP2D6—Dexamethasone—psoriasis	0.00513	0.00744	CbGbCtD
Cyclophosphamide—CYP3A4—Cyclosporine—psoriasis	0.00496	0.00719	CbGbCtD
Cyclophosphamide—ABCB1—Methotrexate—psoriasis	0.00438	0.00635	CbGbCtD
Cyclophosphamide—CYP3A4—Dexamethasone—psoriasis	0.00326	0.00473	CbGbCtD
Cyclophosphamide—CYP2C18—Xenobiotics—CYP2S1—psoriasis	0.00244	0.0492	CbGpPWpGaD
Cyclophosphamide—CYP2A6—CYP2E1 reactions—CYP2S1—psoriasis	0.0024	0.0483	CbGpPWpGaD
Cyclophosphamide—CYP2B6—CYP2E1 reactions—CYP2S1—psoriasis	0.00194	0.039	CbGpPWpGaD
Cyclophosphamide—CYP2C8—CYP2E1 reactions—CYP2S1—psoriasis	0.00164	0.033	CbGpPWpGaD
Cyclophosphamide—CYP3A7—Xenobiotics—CYP2S1—psoriasis	0.00162	0.0327	CbGpPWpGaD
Cyclophosphamide—CYP2A6—Xenobiotics—CYP2S1—psoriasis	0.00149	0.03	CbGpPWpGaD
Cyclophosphamide—CYP2C19—CYP2E1 reactions—CYP2S1—psoriasis	0.00146	0.0295	CbGpPWpGaD
Cyclophosphamide—CYP2D6—CYP2E1 reactions—CYP2S1—psoriasis	0.00135	0.0271	CbGpPWpGaD
Cyclophosphamide—CYP2C9—CYP2E1 reactions—CYP2S1—psoriasis	0.00134	0.0269	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Miscellaneous substrates—CYP2S1—psoriasis	0.00126	0.0253	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Xenobiotics—CYP2S1—psoriasis	0.0012	0.0242	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Xenobiotics—CYP2S1—psoriasis	0.00117	0.0236	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Xenobiotics—CYP2S1—psoriasis	0.00102	0.0205	CbGpPWpGaD
Cyclophosphamide—CYP2C18—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.00101	0.0204	CbGpPWpGaD
Cyclophosphamide—CYP2C18—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.001	0.0201	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Xenobiotics—CYP2S1—psoriasis	0.000908	0.0183	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Xenobiotics—CYP2S1—psoriasis	0.000835	0.0168	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Xenobiotics—CYP2S1—psoriasis	0.000828	0.0167	CbGpPWpGaD
Cyclophosphamide—CYP2C18—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000823	0.0165	CbGpPWpGaD
Cyclophosphamide—ABCB1—Allograft Rejection—IL22—psoriasis	0.000711	0.0143	CbGpPWpGaD
Cyclophosphamide—CYP3A7—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000675	0.0136	CbGpPWpGaD
Cyclophosphamide—CYP3A7—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000666	0.0134	CbGpPWpGaD
Cyclophosphamide—CYP2A6—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000618	0.0124	CbGpPWpGaD
Cyclophosphamide—CYP2A6—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.00061	0.0123	CbGpPWpGaD
Cyclophosphamide—CYP3A7—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000547	0.011	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Xenobiotics—CYP2S1—psoriasis	0.000546	0.011	CbGpPWpGaD
Cyclophosphamide—CYP2A6—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000501	0.0101	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000499	0.01	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000492	0.0099	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000488	0.00981	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000481	0.00968	CbGpPWpGaD
Cyclophosphamide—CYP2C18—Biological oxidations—CYP2S1—psoriasis	0.000437	0.00879	CbGpPWpGaD
Cyclophosphamide—CYP2C18—Metapathway biotransformation—CYP2S1—psoriasis	0.000431	0.00867	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000422	0.0085	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000417	0.00838	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000404	0.00814	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000395	0.00795	CbGpPWpGaD
Cyclophosphamide—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—NFKBIA—psoriasis	0.000387	0.00779	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000377	0.00758	CbGpPWpGaD
Cyclophosphamide—CYP2C18—Tryptophan metabolism—CAT—psoriasis	0.000377	0.00758	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000372	0.00748	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000347	0.00698	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000344	0.00691	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000342	0.00689	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000342	0.00688	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000339	0.00682	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000306	0.00615	CbGpPWpGaD
Cyclophosphamide—ABCB1—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000294	0.00592	CbGpPWpGaD
Cyclophosphamide—CYP3A7—Biological oxidations—CYP2S1—psoriasis	0.000291	0.00584	CbGpPWpGaD
Cyclophosphamide—CYP3A7—Metapathway biotransformation—CYP2S1—psoriasis	0.000287	0.00576	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000281	0.00565	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000279	0.00561	CbGpPWpGaD
Cyclophosphamide—CYP2A6—Biological oxidations—CYP2S1—psoriasis	0.000266	0.00536	CbGpPWpGaD
Cyclophosphamide—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—JUN—psoriasis	0.000257	0.00516	CbGpPWpGaD
Cyclophosphamide—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—NFKB1—psoriasis	0.000247	0.00497	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000229	0.00461	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000227	0.00456	CbGpPWpGaD
Cyclophosphamide—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—VEGFA—psoriasis	0.000224	0.00451	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000224	0.0045	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Biological oxidations—CYP2S1—psoriasis	0.000215	0.00432	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Metapathway biotransformation—CYP2S1—psoriasis	0.000212	0.00426	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Biological oxidations—CYP2S1—psoriasis	0.00021	0.00422	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Metapathway biotransformation—CYP2S1—psoriasis	0.000207	0.00417	CbGpPWpGaD
Cyclophosphamide—CYP2C18—FOXA1 transcription factor network—JUN—psoriasis	0.000188	0.00377	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000184	0.0037	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Biological oxidations—CYP2S1—psoriasis	0.000182	0.00366	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000181	0.00365	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metapathway biotransformation—CYP2S1—psoriasis	0.000179	0.00361	CbGpPWpGaD
Cyclophosphamide—ABCB1—HIF-1-alpha transcription factor network—CP—psoriasis	0.000175	0.00351	CbGpPWpGaD
Cyclophosphamide—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000169	0.0034	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Biological oxidations—CYP2S1—psoriasis	0.000162	0.00327	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metapathway biotransformation—CYP2S1—psoriasis	0.00016	0.00322	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.00016	0.00321	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000158	0.00318	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Melatonin metabolism and effects—APOE—psoriasis	0.000157	0.00317	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Biological oxidations—CYP2S1—psoriasis	0.000149	0.003	CbGpPWpGaD
Cyclophosphamide—CYP2A6—NRF2 pathway—TGFA—psoriasis	0.000148	0.00298	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Biological oxidations—CYP2S1—psoriasis	0.000148	0.00298	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metapathway biotransformation—CYP2S1—psoriasis	0.000147	0.00296	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metapathway biotransformation—CYP2S1—psoriasis	0.000146	0.00294	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Melatonin metabolism and effects—APOE—psoriasis	0.000145	0.00291	CbGpPWpGaD
Cyclophosphamide—ABCB1—Allograft Rejection—HLA-C—psoriasis	0.000135	0.00271	CbGpPWpGaD
Cyclophosphamide—ABCB1—Allograft Rejection—IL13—psoriasis	0.000134	0.00269	CbGpPWpGaD
Cyclophosphamide—ABCB1—Allograft Rejection—IL17A—psoriasis	0.000123	0.00248	CbGpPWpGaD
Cyclophosphamide—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000118	0.00237	CbGpPWpGaD
Cyclophosphamide—ABCB1—Allograft Rejection—IL12B—psoriasis	0.000115	0.0023	CbGpPWpGaD
Cyclophosphamide—ABCB1—Allograft Rejection—HLA-E—psoriasis	0.000112	0.00225	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.00011	0.00221	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000104	0.00209	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Biological oxidations—CYP2S1—psoriasis	9.76e-05	0.00196	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metapathway biotransformation—CYP2S1—psoriasis	9.63e-05	0.00194	CbGpPWpGaD
Cyclophosphamide—CYP2A6—Fluoropyrimidine Activity—TP53—psoriasis	9.5e-05	0.00191	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Melatonin metabolism and effects—NFKB1—psoriasis	9.36e-05	0.00188	CbGpPWpGaD
Cyclophosphamide—ABCB1—Integrated Pancreatic Cancer Pathway—PTTG1—psoriasis	9.26e-05	0.00186	CbGpPWpGaD
Cyclophosphamide—CYP2C18—Metabolism—NDUFA5—psoriasis	8.79e-05	0.00177	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Melatonin metabolism and effects—NFKB1—psoriasis	8.61e-05	0.00173	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Tryptophan metabolism—CAT—psoriasis	8.42e-05	0.00169	CbGpPWpGaD
Cyclophosphamide—ABCB1—Allograft Rejection—IL10—psoriasis	8.38e-05	0.00168	CbGpPWpGaD
Cyclophosphamide—ABCB1—Allograft Rejection—IL4—psoriasis	8.15e-05	0.00164	CbGpPWpGaD
Cyclophosphamide—ABCB1—Allograft Rejection—HLA-B—psoriasis	7.97e-05	0.0016	CbGpPWpGaD
Cyclophosphamide—ABCB1—HIF-1-alpha transcription factor network—LEP—psoriasis	7.96e-05	0.0016	CbGpPWpGaD
Cyclophosphamide—CYP2C18—Metabolism—CYP2S1—psoriasis	7.47e-05	0.0015	CbGpPWpGaD
Cyclophosphamide—ABCB1—HIF-1-alpha transcription factor network—NOS2—psoriasis	7.42e-05	0.00149	CbGpPWpGaD
Cyclophosphamide—ABCB1—Allograft Rejection—HLA-A—psoriasis	7.38e-05	0.00148	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	7.26e-05	0.00146	CbGpPWpGaD
Cyclophosphamide—ABCB1—Allograft Rejection—HLA-DRB1—psoriasis	6.74e-05	0.00136	CbGpPWpGaD
Cyclophosphamide—Ill-defined disorder—Betamethasone—psoriasis	6.15e-05	0.000236	CcSEcCtD
Cyclophosphamide—Ill-defined disorder—Dexamethasone—psoriasis	6.15e-05	0.000236	CcSEcCtD
Cyclophosphamide—Discomfort—Triamcinolone—psoriasis	6.15e-05	0.000236	CcSEcCtD
Cyclophosphamide—Fatigue—Cyclosporine—psoriasis	6.14e-05	0.000236	CcSEcCtD
Cyclophosphamide—Hyperhidrosis—Hydrocortisone—psoriasis	6.12e-05	0.000235	CcSEcCtD
Cyclophosphamide—Stevens-Johnson syndrome—Methotrexate—psoriasis	6.12e-05	0.000235	CcSEcCtD
Cyclophosphamide—Pain—Cyclosporine—psoriasis	6.09e-05	0.000234	CcSEcCtD
Cyclophosphamide—Constipation—Cyclosporine—psoriasis	6.09e-05	0.000234	CcSEcCtD
Cyclophosphamide—Renal failure—Methotrexate—psoriasis	6.07e-05	0.000233	CcSEcCtD
Cyclophosphamide—Decreased appetite—Mycophenolate mofetil—psoriasis	6.04e-05	0.000232	CcSEcCtD
Cyclophosphamide—Anorexia—Hydrocortisone—psoriasis	6.04e-05	0.000232	CcSEcCtD
Cyclophosphamide—Diarrhoea—Mycophenolic acid—psoriasis	6.03e-05	0.000231	CcSEcCtD
Cyclophosphamide—Stomatitis—Methotrexate—psoriasis	6.02e-05	0.000231	CcSEcCtD
Cyclophosphamide—Conjunctivitis—Methotrexate—psoriasis	6e-05	0.00023	CcSEcCtD
Cyclophosphamide—Malaise—Dexamethasone—psoriasis	5.98e-05	0.000229	CcSEcCtD
Cyclophosphamide—Malaise—Betamethasone—psoriasis	5.98e-05	0.000229	CcSEcCtD
Cyclophosphamide—Oedema—Triamcinolone—psoriasis	5.96e-05	0.000229	CcSEcCtD
Cyclophosphamide—Anaphylactic shock—Triamcinolone—psoriasis	5.96e-05	0.000229	CcSEcCtD
Cyclophosphamide—Pain—Mycophenolate mofetil—psoriasis	5.95e-05	0.000228	CcSEcCtD
Cyclophosphamide—Constipation—Mycophenolate mofetil—psoriasis	5.95e-05	0.000228	CcSEcCtD
Cyclophosphamide—Arrhythmia—Prednisone—psoriasis	5.93e-05	0.000227	CcSEcCtD
Cyclophosphamide—Infection—Triamcinolone—psoriasis	5.93e-05	0.000227	CcSEcCtD
Cyclophosphamide—Sweating—Methotrexate—psoriasis	5.92e-05	0.000227	CcSEcCtD
Cyclophosphamide—Hypotension—Hydrocortisone—psoriasis	5.92e-05	0.000227	CcSEcCtD
Cyclophosphamide—Haematuria—Methotrexate—psoriasis	5.89e-05	0.000226	CcSEcCtD
Cyclophosphamide—Feeling abnormal—Cyclosporine—psoriasis	5.87e-05	0.000225	CcSEcCtD
Cyclophosphamide—Shock—Triamcinolone—psoriasis	5.87e-05	0.000225	CcSEcCtD
Cyclophosphamide—Alopecia—Prednisone—psoriasis	5.86e-05	0.000225	CcSEcCtD
Cyclophosphamide—CYP3A7—Metabolism—NDUFA5—psoriasis	5.84e-05	0.00118	CbGpPWpGaD
Cyclophosphamide—Dizziness—Mycophenolic acid—psoriasis	5.83e-05	0.000224	CcSEcCtD
Cyclophosphamide—Paraesthesia—Prednisolone—psoriasis	5.82e-05	0.000223	CcSEcCtD
Cyclophosphamide—Tachycardia—Triamcinolone—psoriasis	5.82e-05	0.000223	CcSEcCtD
Cyclophosphamide—Erythema—Prednisone—psoriasis	5.77e-05	0.000222	CcSEcCtD
Cyclophosphamide—Musculoskeletal discomfort—Hydrocortisone—psoriasis	5.77e-05	0.000221	CcSEcCtD
Cyclophosphamide—Hyperhidrosis—Triamcinolone—psoriasis	5.77e-05	0.000221	CcSEcCtD
Cyclophosphamide—Agranulocytosis—Methotrexate—psoriasis	5.76e-05	0.000221	CcSEcCtD
Cyclophosphamide—Convulsion—Betamethasone—psoriasis	5.75e-05	0.00022	CcSEcCtD
Cyclophosphamide—Convulsion—Dexamethasone—psoriasis	5.75e-05	0.00022	CcSEcCtD
Cyclophosphamide—Feeling abnormal—Mycophenolate mofetil—psoriasis	5.73e-05	0.00022	CcSEcCtD
Cyclophosphamide—Hypertension—Betamethasone—psoriasis	5.72e-05	0.00022	CcSEcCtD
Cyclophosphamide—Hypertension—Dexamethasone—psoriasis	5.72e-05	0.00022	CcSEcCtD
Cyclophosphamide—Paraesthesia—Hydrocortisone—psoriasis	5.69e-05	0.000218	CcSEcCtD
Cyclophosphamide—Urticaria—Cyclosporine—psoriasis	5.66e-05	0.000217	CcSEcCtD
Cyclophosphamide—Myalgia—Betamethasone—psoriasis	5.65e-05	0.000217	CcSEcCtD
Cyclophosphamide—Myalgia—Dexamethasone—psoriasis	5.65e-05	0.000217	CcSEcCtD
Cyclophosphamide—Body temperature increased—Cyclosporine—psoriasis	5.63e-05	0.000216	CcSEcCtD
Cyclophosphamide—Vomiting—Mycophenolic acid—psoriasis	5.6e-05	0.000215	CcSEcCtD
Cyclophosphamide—Discomfort—Dexamethasone—psoriasis	5.58e-05	0.000214	CcSEcCtD
Cyclophosphamide—Discomfort—Betamethasone—psoriasis	5.58e-05	0.000214	CcSEcCtD
Cyclophosphamide—Haemoglobin—Methotrexate—psoriasis	5.57e-05	0.000214	CcSEcCtD
Cyclophosphamide—Rash—Mycophenolic acid—psoriasis	5.55e-05	0.000213	CcSEcCtD
Cyclophosphamide—Dermatitis—Mycophenolic acid—psoriasis	5.55e-05	0.000213	CcSEcCtD
Cyclophosphamide—Pain—Prednisolone—psoriasis	5.55e-05	0.000213	CcSEcCtD
Cyclophosphamide—Hepatitis—Methotrexate—psoriasis	5.54e-05	0.000213	CcSEcCtD
Cyclophosphamide—Haemorrhage—Methotrexate—psoriasis	5.54e-05	0.000213	CcSEcCtD
Cyclophosphamide—Urticaria—Mycophenolate mofetil—psoriasis	5.52e-05	0.000212	CcSEcCtD
Cyclophosphamide—Headache—Mycophenolic acid—psoriasis	5.52e-05	0.000212	CcSEcCtD
Cyclophosphamide—Decreased appetite—Hydrocortisone—psoriasis	5.51e-05	0.000211	CcSEcCtD
Cyclophosphamide—Body temperature increased—Mycophenolate mofetil—psoriasis	5.5e-05	0.000211	CcSEcCtD
Cyclophosphamide—Fatigue—Hydrocortisone—psoriasis	5.46e-05	0.00021	CcSEcCtD
Cyclophosphamide—Vision blurred—Prednisone—psoriasis	5.44e-05	0.000209	CcSEcCtD
Cyclophosphamide—Musculoskeletal discomfort—Triamcinolone—psoriasis	5.43e-05	0.000208	CcSEcCtD
Cyclophosphamide—Pain—Hydrocortisone—psoriasis	5.42e-05	0.000208	CcSEcCtD
Cyclophosphamide—Anaphylactic shock—Dexamethasone—psoriasis	5.41e-05	0.000208	CcSEcCtD
Cyclophosphamide—Oedema—Dexamethasone—psoriasis	5.41e-05	0.000208	CcSEcCtD
Cyclophosphamide—Anaphylactic shock—Betamethasone—psoriasis	5.41e-05	0.000208	CcSEcCtD
Cyclophosphamide—Oedema—Betamethasone—psoriasis	5.41e-05	0.000208	CcSEcCtD
Cyclophosphamide—Infection—Dexamethasone—psoriasis	5.38e-05	0.000206	CcSEcCtD
Cyclophosphamide—Infection—Betamethasone—psoriasis	5.38e-05	0.000206	CcSEcCtD
Cyclophosphamide—Ill-defined disorder—Prednisone—psoriasis	5.36e-05	0.000206	CcSEcCtD
Cyclophosphamide—CYP2A6—Metabolism—NDUFA5—psoriasis	5.36e-05	0.00108	CbGpPWpGaD
Cyclophosphamide—Paraesthesia—Triamcinolone—psoriasis	5.36e-05	0.000205	CcSEcCtD
Cyclophosphamide—Feeling abnormal—Prednisolone—psoriasis	5.34e-05	0.000205	CcSEcCtD
Cyclophosphamide—Visual impairment—Methotrexate—psoriasis	5.34e-05	0.000205	CcSEcCtD
Cyclophosphamide—Anaemia—Prednisone—psoriasis	5.34e-05	0.000205	CcSEcCtD
Cyclophosphamide—Shock—Dexamethasone—psoriasis	5.32e-05	0.000204	CcSEcCtD
Cyclophosphamide—Shock—Betamethasone—psoriasis	5.32e-05	0.000204	CcSEcCtD
Cyclophosphamide—Dyspnoea—Triamcinolone—psoriasis	5.32e-05	0.000204	CcSEcCtD
Cyclophosphamide—Agitation—Prednisone—psoriasis	5.31e-05	0.000204	CcSEcCtD
Cyclophosphamide—Thrombocytopenia—Betamethasone—psoriasis	5.3e-05	0.000203	CcSEcCtD
Cyclophosphamide—Thrombocytopenia—Dexamethasone—psoriasis	5.3e-05	0.000203	CcSEcCtD
Cyclophosphamide—Tachycardia—Betamethasone—psoriasis	5.28e-05	0.000203	CcSEcCtD
Cyclophosphamide—Tachycardia—Dexamethasone—psoriasis	5.28e-05	0.000203	CcSEcCtD
Cyclophosphamide—Hypersensitivity—Cyclosporine—psoriasis	5.25e-05	0.000201	CcSEcCtD
Cyclophosphamide—Erythema multiforme—Methotrexate—psoriasis	5.24e-05	0.000201	CcSEcCtD
Cyclophosphamide—Nausea—Mycophenolic acid—psoriasis	5.23e-05	0.000201	CcSEcCtD
Cyclophosphamide—Hyperhidrosis—Betamethasone—psoriasis	5.23e-05	0.000201	CcSEcCtD
Cyclophosphamide—Hyperhidrosis—Dexamethasone—psoriasis	5.23e-05	0.000201	CcSEcCtD
Cyclophosphamide—Feeling abnormal—Hydrocortisone—psoriasis	5.22e-05	0.0002	CcSEcCtD
Cyclophosphamide—Malaise—Prednisone—psoriasis	5.21e-05	0.0002	CcSEcCtD
Cyclophosphamide—Tinnitus—Methotrexate—psoriasis	5.17e-05	0.000198	CcSEcCtD
Cyclophosphamide—Anorexia—Dexamethasone—psoriasis	5.16e-05	0.000198	CcSEcCtD
Cyclophosphamide—Anorexia—Betamethasone—psoriasis	5.16e-05	0.000198	CcSEcCtD
Cyclophosphamide—Urticaria—Prednisolone—psoriasis	5.15e-05	0.000198	CcSEcCtD
Cyclophosphamide—Fatigue—Triamcinolone—psoriasis	5.14e-05	0.000197	CcSEcCtD
Cyclophosphamide—Hypersensitivity—Mycophenolate mofetil—psoriasis	5.12e-05	0.000197	CcSEcCtD
Cyclophosphamide—Asthenia—Cyclosporine—psoriasis	5.11e-05	0.000196	CcSEcCtD
Cyclophosphamide—Pain—Triamcinolone—psoriasis	5.1e-05	0.000196	CcSEcCtD
Cyclophosphamide—Hypotension—Betamethasone—psoriasis	5.06e-05	0.000194	CcSEcCtD
Cyclophosphamide—Hypotension—Dexamethasone—psoriasis	5.06e-05	0.000194	CcSEcCtD
Cyclophosphamide—Pruritus—Cyclosporine—psoriasis	5.04e-05	0.000193	CcSEcCtD
Cyclophosphamide—Urticaria—Hydrocortisone—psoriasis	5.03e-05	0.000193	CcSEcCtD
Cyclophosphamide—Body temperature increased—Hydrocortisone—psoriasis	5.01e-05	0.000192	CcSEcCtD
Cyclophosphamide—Convulsion—Prednisone—psoriasis	5e-05	0.000192	CcSEcCtD
Cyclophosphamide—Asthenia—Mycophenolate mofetil—psoriasis	4.99e-05	0.000191	CcSEcCtD
Cyclophosphamide—Hypertension—Prednisone—psoriasis	4.99e-05	0.000191	CcSEcCtD
Cyclophosphamide—Chills—Methotrexate—psoriasis	4.97e-05	0.000191	CcSEcCtD
Cyclophosphamide—CYP3A7—Metabolism—CYP2S1—psoriasis	4.97e-05	0.000999	CbGpPWpGaD
Cyclophosphamide—Musculoskeletal discomfort—Dexamethasone—psoriasis	4.93e-05	0.000189	CcSEcCtD
Cyclophosphamide—Musculoskeletal discomfort—Betamethasone—psoriasis	4.93e-05	0.000189	CcSEcCtD
Cyclophosphamide—ABCB1—Allograft Rejection—IFNG—psoriasis	4.93e-05	0.000991	CbGpPWpGaD
Cyclophosphamide—Pruritus—Mycophenolate mofetil—psoriasis	4.92e-05	0.000189	CcSEcCtD
Cyclophosphamide—ABCB1—HIF-1-alpha transcription factor network—JUN—psoriasis	4.92e-05	0.000989	CbGpPWpGaD
Cyclophosphamide—Myalgia—Prednisone—psoriasis	4.92e-05	0.000189	CcSEcCtD
Cyclophosphamide—Arthralgia—Prednisone—psoriasis	4.92e-05	0.000189	CcSEcCtD
Cyclophosphamide—Feeling abnormal—Triamcinolone—psoriasis	4.91e-05	0.000189	CcSEcCtD
Cyclophosphamide—Alopecia—Methotrexate—psoriasis	4.9e-05	0.000188	CcSEcCtD
Cyclophosphamide—Diarrhoea—Cyclosporine—psoriasis	4.88e-05	0.000187	CcSEcCtD
Cyclophosphamide—Paraesthesia—Dexamethasone—psoriasis	4.86e-05	0.000186	CcSEcCtD
Cyclophosphamide—Paraesthesia—Betamethasone—psoriasis	4.86e-05	0.000186	CcSEcCtD
Cyclophosphamide—Discomfort—Prednisone—psoriasis	4.86e-05	0.000186	CcSEcCtD
Cyclophosphamide—Erythema—Methotrexate—psoriasis	4.83e-05	0.000185	CcSEcCtD
Cyclophosphamide—Hypersensitivity—Prednisolone—psoriasis	4.78e-05	0.000183	CcSEcCtD
Cyclophosphamide—Diarrhoea—Mycophenolate mofetil—psoriasis	4.76e-05	0.000183	CcSEcCtD
Cyclophosphamide—Urticaria—Triamcinolone—psoriasis	4.74e-05	0.000182	CcSEcCtD
Cyclophosphamide—Dysgeusia—Methotrexate—psoriasis	4.73e-05	0.000181	CcSEcCtD
Cyclophosphamide—Body temperature increased—Triamcinolone—psoriasis	4.71e-05	0.000181	CcSEcCtD
Cyclophosphamide—Dizziness—Cyclosporine—psoriasis	4.71e-05	0.000181	CcSEcCtD
Cyclophosphamide—Oedema—Prednisone—psoriasis	4.71e-05	0.000181	CcSEcCtD
Cyclophosphamide—Anaphylactic shock—Prednisone—psoriasis	4.71e-05	0.000181	CcSEcCtD
Cyclophosphamide—Decreased appetite—Dexamethasone—psoriasis	4.7e-05	0.00018	CcSEcCtD
Cyclophosphamide—Decreased appetite—Betamethasone—psoriasis	4.7e-05	0.00018	CcSEcCtD
Cyclophosphamide—Infection—Prednisone—psoriasis	4.68e-05	0.00018	CcSEcCtD
Cyclophosphamide—Hypersensitivity—Hydrocortisone—psoriasis	4.67e-05	0.000179	CcSEcCtD
Cyclophosphamide—Fatigue—Betamethasone—psoriasis	4.67e-05	0.000179	CcSEcCtD
Cyclophosphamide—Fatigue—Dexamethasone—psoriasis	4.67e-05	0.000179	CcSEcCtD
Cyclophosphamide—Shock—Prednisone—psoriasis	4.64e-05	0.000178	CcSEcCtD
Cyclophosphamide—Pain—Betamethasone—psoriasis	4.63e-05	0.000178	CcSEcCtD
Cyclophosphamide—Pain—Dexamethasone—psoriasis	4.63e-05	0.000178	CcSEcCtD
Cyclophosphamide—Tachycardia—Prednisone—psoriasis	4.6e-05	0.000176	CcSEcCtD
Cyclophosphamide—Dizziness—Mycophenolate mofetil—psoriasis	4.6e-05	0.000176	CcSEcCtD
Cyclophosphamide—ABCB1—Allograft Rejection—CXCL8—psoriasis	4.58e-05	0.000921	CbGpPWpGaD
Cyclophosphamide—Hyperhidrosis—Prednisone—psoriasis	4.56e-05	0.000175	CcSEcCtD
Cyclophosphamide—CYP2A6—Metabolism—CYP2S1—psoriasis	4.55e-05	0.000916	CbGpPWpGaD
Cyclophosphamide—Vision blurred—Methotrexate—psoriasis	4.55e-05	0.000174	CcSEcCtD
Cyclophosphamide—Asthenia—Hydrocortisone—psoriasis	4.54e-05	0.000174	CcSEcCtD
Cyclophosphamide—Vomiting—Cyclosporine—psoriasis	4.53e-05	0.000174	CcSEcCtD
Cyclophosphamide—Rash—Cyclosporine—psoriasis	4.49e-05	0.000172	CcSEcCtD
Cyclophosphamide—Anorexia—Prednisone—psoriasis	4.49e-05	0.000172	CcSEcCtD
Cyclophosphamide—Dermatitis—Cyclosporine—psoriasis	4.49e-05	0.000172	CcSEcCtD
Cyclophosphamide—Pruritus—Hydrocortisone—psoriasis	4.48e-05	0.000172	CcSEcCtD
Cyclophosphamide—Ill-defined disorder—Methotrexate—psoriasis	4.48e-05	0.000172	CcSEcCtD
Cyclophosphamide—Headache—Cyclosporine—psoriasis	4.46e-05	0.000171	CcSEcCtD
Cyclophosphamide—Anaemia—Methotrexate—psoriasis	4.46e-05	0.000171	CcSEcCtD
Cyclophosphamide—Feeling abnormal—Dexamethasone—psoriasis	4.46e-05	0.000171	CcSEcCtD
Cyclophosphamide—Feeling abnormal—Betamethasone—psoriasis	4.46e-05	0.000171	CcSEcCtD
Cyclophosphamide—Vomiting—Mycophenolate mofetil—psoriasis	4.42e-05	0.00017	CcSEcCtD
Cyclophosphamide—Hypersensitivity—Triamcinolone—psoriasis	4.39e-05	0.000169	CcSEcCtD
Cyclophosphamide—Rash—Mycophenolate mofetil—psoriasis	4.38e-05	0.000168	CcSEcCtD
Cyclophosphamide—Dermatitis—Mycophenolate mofetil—psoriasis	4.38e-05	0.000168	CcSEcCtD
Cyclophosphamide—Headache—Mycophenolate mofetil—psoriasis	4.36e-05	0.000167	CcSEcCtD
Cyclophosphamide—Malaise—Methotrexate—psoriasis	4.35e-05	0.000167	CcSEcCtD
Cyclophosphamide—Diarrhoea—Hydrocortisone—psoriasis	4.33e-05	0.000166	CcSEcCtD
Cyclophosphamide—CYP2B6—Metabolism—NDUFA5—psoriasis	4.32e-05	0.000869	CbGpPWpGaD
Cyclophosphamide—Leukopenia—Methotrexate—psoriasis	4.32e-05	0.000166	CcSEcCtD
Cyclophosphamide—Urticaria—Betamethasone—psoriasis	4.3e-05	0.000165	CcSEcCtD
Cyclophosphamide—Urticaria—Dexamethasone—psoriasis	4.3e-05	0.000165	CcSEcCtD
Cyclophosphamide—ABCB1—HIF-1-alpha transcription factor network—VEGFA—psoriasis	4.3e-05	0.000864	CbGpPWpGaD
Cyclophosphamide—Musculoskeletal discomfort—Prednisone—psoriasis	4.29e-05	0.000165	CcSEcCtD
Cyclophosphamide—Dizziness—Prednisolone—psoriasis	4.29e-05	0.000165	CcSEcCtD
Cyclophosphamide—Asthenia—Triamcinolone—psoriasis	4.28e-05	0.000164	CcSEcCtD
Cyclophosphamide—Body temperature increased—Dexamethasone—psoriasis	4.28e-05	0.000164	CcSEcCtD
Cyclophosphamide—Body temperature increased—Betamethasone—psoriasis	4.28e-05	0.000164	CcSEcCtD
Cyclophosphamide—Nausea—Cyclosporine—psoriasis	4.23e-05	0.000162	CcSEcCtD
Cyclophosphamide—Paraesthesia—Prednisone—psoriasis	4.23e-05	0.000162	CcSEcCtD
Cyclophosphamide—CYP3A5—Metabolism—NDUFA5—psoriasis	4.22e-05	0.00085	CbGpPWpGaD
Cyclophosphamide—Pruritus—Triamcinolone—psoriasis	4.22e-05	0.000162	CcSEcCtD
Cyclophosphamide—Cough—Methotrexate—psoriasis	4.21e-05	0.000162	CcSEcCtD
Cyclophosphamide—Dizziness—Hydrocortisone—psoriasis	4.19e-05	0.000161	CcSEcCtD
Cyclophosphamide—Convulsion—Methotrexate—psoriasis	4.18e-05	0.00016	CcSEcCtD
Cyclophosphamide—Nausea—Mycophenolate mofetil—psoriasis	4.13e-05	0.000158	CcSEcCtD
Cyclophosphamide—Myalgia—Methotrexate—psoriasis	4.11e-05	0.000158	CcSEcCtD
Cyclophosphamide—Chest pain—Methotrexate—psoriasis	4.11e-05	0.000158	CcSEcCtD
Cyclophosphamide—Arthralgia—Methotrexate—psoriasis	4.11e-05	0.000158	CcSEcCtD
Cyclophosphamide—Decreased appetite—Prednisone—psoriasis	4.1e-05	0.000157	CcSEcCtD
Cyclophosphamide—Rash—Prednisolone—psoriasis	4.09e-05	0.000157	CcSEcCtD
Cyclophosphamide—Dermatitis—Prednisolone—psoriasis	4.09e-05	0.000157	CcSEcCtD
Cyclophosphamide—Fatigue—Prednisone—psoriasis	4.06e-05	0.000156	CcSEcCtD
Cyclophosphamide—Headache—Prednisolone—psoriasis	4.06e-05	0.000156	CcSEcCtD
Cyclophosphamide—Discomfort—Methotrexate—psoriasis	4.06e-05	0.000156	CcSEcCtD
Cyclophosphamide—Constipation—Prednisone—psoriasis	4.03e-05	0.000155	CcSEcCtD
Cyclophosphamide—Vomiting—Hydrocortisone—psoriasis	4.03e-05	0.000155	CcSEcCtD
Cyclophosphamide—Rash—Hydrocortisone—psoriasis	3.99e-05	0.000153	CcSEcCtD
Cyclophosphamide—Dermatitis—Hydrocortisone—psoriasis	3.99e-05	0.000153	CcSEcCtD
Cyclophosphamide—Confusional state—Methotrexate—psoriasis	3.97e-05	0.000152	CcSEcCtD
Cyclophosphamide—Headache—Hydrocortisone—psoriasis	3.97e-05	0.000152	CcSEcCtD
Cyclophosphamide—Dizziness—Triamcinolone—psoriasis	3.94e-05	0.000151	CcSEcCtD
Cyclophosphamide—Anaphylactic shock—Methotrexate—psoriasis	3.94e-05	0.000151	CcSEcCtD
Cyclophosphamide—Infection—Methotrexate—psoriasis	3.91e-05	0.00015	CcSEcCtD
Cyclophosphamide—Feeling abnormal—Prednisone—psoriasis	3.88e-05	0.000149	CcSEcCtD
Cyclophosphamide—Asthenia—Dexamethasone—psoriasis	3.88e-05	0.000149	CcSEcCtD
Cyclophosphamide—Asthenia—Betamethasone—psoriasis	3.88e-05	0.000149	CcSEcCtD
Cyclophosphamide—Thrombocytopenia—Methotrexate—psoriasis	3.86e-05	0.000148	CcSEcCtD
Cyclophosphamide—Nausea—Prednisolone—psoriasis	3.85e-05	0.000148	CcSEcCtD
Cyclophosphamide—Pruritus—Dexamethasone—psoriasis	3.83e-05	0.000147	CcSEcCtD
Cyclophosphamide—Pruritus—Betamethasone—psoriasis	3.83e-05	0.000147	CcSEcCtD
Cyclophosphamide—Hyperhidrosis—Methotrexate—psoriasis	3.81e-05	0.000146	CcSEcCtD
Cyclophosphamide—Vomiting—Triamcinolone—psoriasis	3.79e-05	0.000145	CcSEcCtD
Cyclophosphamide—ABCB1—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	3.77e-05	0.000759	CbGpPWpGaD
Cyclophosphamide—Nausea—Hydrocortisone—psoriasis	3.76e-05	0.000144	CcSEcCtD
Cyclophosphamide—Rash—Triamcinolone—psoriasis	3.76e-05	0.000144	CcSEcCtD
Cyclophosphamide—Dermatitis—Triamcinolone—psoriasis	3.76e-05	0.000144	CcSEcCtD
Cyclophosphamide—Anorexia—Methotrexate—psoriasis	3.75e-05	0.000144	CcSEcCtD
Cyclophosphamide—Urticaria—Prednisone—psoriasis	3.74e-05	0.000144	CcSEcCtD
Cyclophosphamide—Headache—Triamcinolone—psoriasis	3.74e-05	0.000143	CcSEcCtD
Cyclophosphamide—Body temperature increased—Prednisone—psoriasis	3.73e-05	0.000143	CcSEcCtD
Cyclophosphamide—ABCB1—Allograft Rejection—VEGFA—psoriasis	3.72e-05	0.000748	CbGpPWpGaD
Cyclophosphamide—Diarrhoea—Dexamethasone—psoriasis	3.7e-05	0.000142	CcSEcCtD
Cyclophosphamide—Diarrhoea—Betamethasone—psoriasis	3.7e-05	0.000142	CcSEcCtD
Cyclophosphamide—Hypotension—Methotrexate—psoriasis	3.68e-05	0.000141	CcSEcCtD
Cyclophosphamide—CYP2B6—Metabolism—CYP2S1—psoriasis	3.67e-05	0.000739	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism—NDUFA5—psoriasis	3.66e-05	0.000736	CbGpPWpGaD
Cyclophosphamide—CYP2C18—Metabolism—CARM1—psoriasis	3.65e-05	0.000734	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Metabolism—CYP2S1—psoriasis	3.59e-05	0.000722	CbGpPWpGaD
Cyclophosphamide—Musculoskeletal discomfort—Methotrexate—psoriasis	3.59e-05	0.000138	CcSEcCtD
Cyclophosphamide—Dizziness—Betamethasone—psoriasis	3.58e-05	0.000137	CcSEcCtD
Cyclophosphamide—Dizziness—Dexamethasone—psoriasis	3.58e-05	0.000137	CcSEcCtD
Cyclophosphamide—Nausea—Triamcinolone—psoriasis	3.54e-05	0.000136	CcSEcCtD
Cyclophosphamide—Paraesthesia—Methotrexate—psoriasis	3.54e-05	0.000136	CcSEcCtD
Cyclophosphamide—Dyspnoea—Methotrexate—psoriasis	3.51e-05	0.000135	CcSEcCtD
Cyclophosphamide—Hypersensitivity—Prednisone—psoriasis	3.47e-05	0.000133	CcSEcCtD
Cyclophosphamide—Vomiting—Dexamethasone—psoriasis	3.44e-05	0.000132	CcSEcCtD
Cyclophosphamide—Vomiting—Betamethasone—psoriasis	3.44e-05	0.000132	CcSEcCtD
Cyclophosphamide—Decreased appetite—Methotrexate—psoriasis	3.42e-05	0.000131	CcSEcCtD
Cyclophosphamide—Rash—Dexamethasone—psoriasis	3.41e-05	0.000131	CcSEcCtD
Cyclophosphamide—Rash—Betamethasone—psoriasis	3.41e-05	0.000131	CcSEcCtD
Cyclophosphamide—CYP2C8—Metabolism of lipids and lipoproteins—CARM1—psoriasis	3.41e-05	0.000686	CbGpPWpGaD
Cyclophosphamide—Dermatitis—Dexamethasone—psoriasis	3.41e-05	0.000131	CcSEcCtD
Cyclophosphamide—Dermatitis—Betamethasone—psoriasis	3.41e-05	0.000131	CcSEcCtD
Cyclophosphamide—Fatigue—Methotrexate—psoriasis	3.4e-05	0.00013	CcSEcCtD
Cyclophosphamide—Headache—Dexamethasone—psoriasis	3.39e-05	0.00013	CcSEcCtD
Cyclophosphamide—Headache—Betamethasone—psoriasis	3.39e-05	0.00013	CcSEcCtD
Cyclophosphamide—Asthenia—Prednisone—psoriasis	3.38e-05	0.00013	CcSEcCtD
Cyclophosphamide—Pain—Methotrexate—psoriasis	3.37e-05	0.000129	CcSEcCtD
Cyclophosphamide—Pruritus—Prednisone—psoriasis	3.33e-05	0.000128	CcSEcCtD
Cyclophosphamide—CYP2C19—Metabolism—NDUFA5—psoriasis	3.27e-05	0.000657	CbGpPWpGaD
Cyclophosphamide—Feeling abnormal—Methotrexate—psoriasis	3.25e-05	0.000125	CcSEcCtD
Cyclophosphamide—Diarrhoea—Prednisone—psoriasis	3.22e-05	0.000124	CcSEcCtD
Cyclophosphamide—Nausea—Betamethasone—psoriasis	3.21e-05	0.000123	CcSEcCtD
Cyclophosphamide—Nausea—Dexamethasone—psoriasis	3.21e-05	0.000123	CcSEcCtD
Cyclophosphamide—ABCB1—Allograft Rejection—TNF—psoriasis	3.19e-05	0.000641	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—NDUFA5—psoriasis	3.19e-05	0.000641	CbGpPWpGaD
Cyclophosphamide—ABCB1—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	3.17e-05	0.000637	CbGpPWpGaD
Cyclophosphamide—Urticaria—Methotrexate—psoriasis	3.13e-05	0.00012	CcSEcCtD
Cyclophosphamide—Dizziness—Prednisone—psoriasis	3.12e-05	0.00012	CcSEcCtD
Cyclophosphamide—Body temperature increased—Methotrexate—psoriasis	3.11e-05	0.000119	CcSEcCtD
Cyclophosphamide—CYP2C8—Metabolism—CYP2S1—psoriasis	3.11e-05	0.000626	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism of lipids and lipoproteins—CARM1—psoriasis	3.04e-05	0.000612	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—NDUFA5—psoriasis	3e-05	0.000604	CbGpPWpGaD
Cyclophosphamide—Vomiting—Prednisone—psoriasis	3e-05	0.000115	CcSEcCtD
Cyclophosphamide—CYP2C9—Metabolism—NDUFA5—psoriasis	2.98e-05	0.000599	CbGpPWpGaD
Cyclophosphamide—Rash—Prednisone—psoriasis	2.97e-05	0.000114	CcSEcCtD
Cyclophosphamide—Dermatitis—Prednisone—psoriasis	2.97e-05	0.000114	CcSEcCtD
Cyclophosphamide—ABCB1—Transmembrane transport of small molecules—CP—psoriasis	2.96e-05	0.000596	CbGpPWpGaD
Cyclophosphamide—Headache—Prednisone—psoriasis	2.95e-05	0.000113	CcSEcCtD
Cyclophosphamide—Hypersensitivity—Methotrexate—psoriasis	2.9e-05	0.000111	CcSEcCtD
Cyclophosphamide—Asthenia—Methotrexate—psoriasis	2.83e-05	0.000108	CcSEcCtD
Cyclophosphamide—ABCB1—Transmembrane transport of small molecules—CARM1—psoriasis	2.83e-05	0.000568	CbGpPWpGaD
Cyclophosphamide—Nausea—Prednisone—psoriasis	2.8e-05	0.000107	CcSEcCtD
Cyclophosphamide—Pruritus—Methotrexate—psoriasis	2.79e-05	0.000107	CcSEcCtD
Cyclophosphamide—CYP2C19—Metabolism—CYP2S1—psoriasis	2.78e-05	0.000558	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.78e-05	0.000558	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—CYP2S1—psoriasis	2.71e-05	0.000545	CbGpPWpGaD
Cyclophosphamide—Diarrhoea—Methotrexate—psoriasis	2.69e-05	0.000103	CcSEcCtD
Cyclophosphamide—Dizziness—Methotrexate—psoriasis	2.6e-05	9.99e-05	CcSEcCtD
Cyclophosphamide—CYP2D6—Metabolism—CYP2S1—psoriasis	2.55e-05	0.000514	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—CYP2S1—psoriasis	2.53e-05	0.000509	CbGpPWpGaD
Cyclophosphamide—Vomiting—Methotrexate—psoriasis	2.5e-05	9.61e-05	CcSEcCtD
Cyclophosphamide—Rash—Methotrexate—psoriasis	2.48e-05	9.53e-05	CcSEcCtD
Cyclophosphamide—Dermatitis—Methotrexate—psoriasis	2.48e-05	9.52e-05	CcSEcCtD
Cyclophosphamide—Headache—Methotrexate—psoriasis	2.47e-05	9.47e-05	CcSEcCtD
Cyclophosphamide—CYP3A7—Metabolism—CARM1—psoriasis	2.43e-05	0.000488	CbGpPWpGaD
Cyclophosphamide—Nausea—Methotrexate—psoriasis	2.34e-05	8.98e-05	CcSEcCtD
Cyclophosphamide—CYP2C18—Metabolism—CAT—psoriasis	2.24e-05	0.000452	CbGpPWpGaD
Cyclophosphamide—CYP2A6—Metabolism—CARM1—psoriasis	2.22e-05	0.000447	CbGpPWpGaD
Cyclophosphamide—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	2.1e-05	0.000423	CbGpPWpGaD
Cyclophosphamide—ABCB1—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	2.02e-05	0.000407	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—NDUFA5—psoriasis	1.96e-05	0.000395	CbGpPWpGaD
Cyclophosphamide—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	1.84e-05	0.000369	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Metabolism—CARM1—psoriasis	1.79e-05	0.000361	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Metabolism—CARM1—psoriasis	1.75e-05	0.000353	CbGpPWpGaD
Cyclophosphamide—CYP2C18—Metabolism—APOE—psoriasis	1.74e-05	0.000351	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—CYP2S1—psoriasis	1.67e-05	0.000336	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.63e-05	0.000328	CbGpPWpGaD
Cyclophosphamide—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	1.57e-05	0.000316	CbGpPWpGaD
Cyclophosphamide—CYP2C18—Metabolism—PPARG—psoriasis	1.52e-05	0.000306	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism—CARM1—psoriasis	1.52e-05	0.000306	CbGpPWpGaD
Cyclophosphamide—CYP3A7—Metabolism—CAT—psoriasis	1.49e-05	0.0003	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.46e-05	0.000293	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.42e-05	0.000286	CbGpPWpGaD
Cyclophosphamide—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	1.39e-05	0.000279	CbGpPWpGaD
Cyclophosphamide—CYP2A6—Metabolism—CAT—psoriasis	1.37e-05	0.000275	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—CARM1—psoriasis	1.36e-05	0.000273	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.33e-05	0.000267	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—CARM1—psoriasis	1.32e-05	0.000266	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.27e-05	0.000255	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—CARM1—psoriasis	1.25e-05	0.000251	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—CARM1—psoriasis	1.24e-05	0.000249	CbGpPWpGaD
Cyclophosphamide—CYP3A7—Metabolism—APOE—psoriasis	1.16e-05	0.000233	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.16e-05	0.000232	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Metabolism—CAT—psoriasis	1.1e-05	0.000222	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Metabolism—CAT—psoriasis	1.08e-05	0.000217	CbGpPWpGaD
Cyclophosphamide—CYP2A6—Metabolism—APOE—psoriasis	1.06e-05	0.000214	CbGpPWpGaD
Cyclophosphamide—CYP3A7—Metabolism—PPARG—psoriasis	1.01e-05	0.000203	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism—CAT—psoriasis	9.34e-06	0.000188	CbGpPWpGaD
Cyclophosphamide—CYP2A6—Metabolism—PPARG—psoriasis	9.26e-06	0.000186	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Metabolism—APOE—psoriasis	8.58e-06	0.000172	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Metabolism—APOE—psoriasis	8.38e-06	0.000169	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—CAT—psoriasis	8.34e-06	0.000168	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—CARM1—psoriasis	8.15e-06	0.000164	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—CAT—psoriasis	8.14e-06	0.000164	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—CAT—psoriasis	7.67e-06	0.000154	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—CAT—psoriasis	7.6e-06	0.000153	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Metabolism—PPARG—psoriasis	7.47e-06	0.00015	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Metabolism—PPARG—psoriasis	7.3e-06	0.000147	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism—APOE—psoriasis	7.26e-06	0.000146	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—APOE—psoriasis	6.48e-06	0.00013	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—APOE—psoriasis	6.33e-06	0.000127	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism—PPARG—psoriasis	6.32e-06	0.000127	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—APOE—psoriasis	5.96e-06	0.00012	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—APOE—psoriasis	5.91e-06	0.000119	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—PPARG—psoriasis	5.64e-06	0.000114	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—PPARG—psoriasis	5.51e-06	0.000111	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—PPARG—psoriasis	5.19e-06	0.000104	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—PPARG—psoriasis	5.15e-06	0.000104	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—CAT—psoriasis	5.02e-06	0.000101	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—APOE—psoriasis	3.9e-06	7.84e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—PPARG—psoriasis	3.39e-06	6.83e-05	CbGpPWpGaD
